Compare Johnson & Johnson (JNJ) vs Range Resources Corporation Common Stock (RRC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Range Resources Corporation Common Stock — how do they compare? Johnson & Johnson trades at $258.07 (market cap $599.12B), while Range Resources Corporation Common Stock trades at $41.78 (market cap $9.93B). The key difference: Johnson & Johnson is far larger — about 60.3× Range Resources Corporation Common Stock's market cap, and Johnson & Johnson pays the higher dividend (2.16%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Range Resources Corporation Common Stock for 0 Days on average.
| JNJ | RRC | |
|---|---|---|
Market Cap | $599.12B | $9.93B |
Volume | 16,640,951 | 2,413,752 |
Sector | Health | Energy |
52-Week High | $278.43 | $47.65 |
52-Week Low | $186.00 | $33.43 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $627.40B | $10.94B |
Dividend Yield | 2.16% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.
The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.
Range Resources (RRC) trades at $42.48, up 2.56% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows solid fundamentals with a P/E of 11.73 and net income margin of 26.32%, while technical indicators signal neutral momentum near key resistance at $43. Recent institutional buying and positive analyst coverage (38.71% buy ratings) support the bullish case.
Outlook remains positive with Q3 2026 earnings expected at $0.776 per share and consensus price target of $44.00 offering 3.6% upside. Risks include energy price volatility and negative net cash flow of -$304M in 2025, though improved 2026 projections show operating cash flow growth to $1.4B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Range Resources Corporation Common Stock
Range Resources Corporation is an independent natural gas and natural gas liquids producer operating in the Appalachian Basin, primarily the Marcellus Shale in Pennsylvania, handling drilling, completion, and gathering and transportation connections for its production.
Read more on RRC →
